Brief: Citius Pharmaceuticals Advances Mino-Lok Phase 3 Trial Achieving 85 Of 92 Events To Date
24/04/2023 14:31
April 24 (Reuters) - Citius Pharmaceuticals Inc
CTXR.O :
* CITIUS PHARMACEUTICALS ADVANCES MINO-LOK® PHASE 3 TRIAL
ACHIEVING 85 OF 92 EVENTS TO DATE
* CITIUS PHARMACEUTICALS INC - MULTI-CENTER MINO-LOK PHASE 3
TRIAL
CONTINUES TO RECRUIT PATIENTS AT 35 CLINICAL TRIAL SITES IN U.S.
AND INDIA
Source text for Eikon: ID:nPn7t88sva
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules